Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 11/20 | 0.49 |
| ▸ | CA1 | P00915 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 11/20 | 0.49 |
| ▸ | CA12 | O43570 | 9/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154497 | 0.91 | CA12 (0.60) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL5527165 | 0.85 | ALDH1A1 (0.46) | CA9CA1CA2CA12ALDH1A1 | |
| SCHEMBL5533607 | 0.80 | CA12 (0.65) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL14502329 | 0.78 | CA1 (0.69) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL5150616 | 0.77 | ALDH1A1 (0.53) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL481618 | 0.75 | CA9 (0.69) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL29541147 | 0.75 | CA9 (0.69) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL26763060 | 0.73 | CA1 (0.61) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL5533314 | 0.72 | CA12 (0.79) | CA9CA1CA2CA12SCN2A | |
| SCHEMBL9468558 | 0.70 | TSHR (0.69) | CA9CA1CA2CA12SCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | claimed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | CA9 3754/4885CA1 847/4885CA2 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.